UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer

Journal of oncology pharmacy practice, 2022-10, Vol.28 (7), p.1674-1676

Giuliani, Jacopo

2022

Volltextzugriff (PDF)

Cost-effectiveness of denosumab in preventing skeletal-related events in bone metastases

Journal of oncology pharmacy practice, 2021-12, Vol.27 (8), p.2000-2003

Giuliani, Jacopo

2021

Volltextzugriff (PDF)

The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer

Journal of oncology pharmacy practice, 2020-09, Vol.26 (6), p.1486-1491

2020

Volltextzugriff (PDF)

Cost-effectiveness of immune checkpoint inhibitors and radiotherapy in advanced non-small cell lung cancer

Journal of oncology pharmacy practice, 2021-12, Vol.27 (8), p.2004-2006

2021

Volltextzugriff (PDF)

Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data

Current opinion in oncology, 2020-07, Vol.32 (4), p.269-273

2020

Volltextzugriff (PDF)

Implications of drugs with rebate in Europe

The Lancet regional health. Europe, 2021-04, Vol.3, p.100060-100060, Article 100060

2021

Volltextzugriff (PDF)

The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma

Journal of oncology pharmacy practice, 2022-03, Vol.28 (2), p.434-437

2022

Volltextzugriff (PDF)

Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer

Journal of oncology pharmacy practice, 2022-01, Vol.28 (1), p.199-202

2022

Volltextzugriff (PDF)

Cost-effectiveness of maintenance therapy after first-line treatment in metastatic colorectal cancer

Journal of oncology pharmacy practice, 2022-01, Vol.28 (1), p.194-198

2022

Volltextzugriff (PDF)

Netupitant plus palonosetron is a cost-effective treatment for the prophylaxis of chemotherapy-induced nausea and vomiting in highly and moderately emetogenic cancer treatment

Expert review of pharmacoeconomics & outcomes research, 2019-09, Vol.19 (5), p.505-508

2019

Volltextzugriff (PDF)

Cost-effectiveness of consolidation durvalumab after chemo-radiotherapy in stage III non-small-cell lung cancer: A cost-effective change

Journal of oncology pharmacy practice, 2022-03, Vol.28 (2), p.438-441

2022

Volltextzugriff (PDF)

Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer

Journal of oncology pharmacy practice, 2023-03, Vol.29 (2), p.457-464

2023

Volltextzugriff (PDF)

Acute Liver Failure Caused by Metastatic Breast Cancer: Can We Expect Some Results from Chemotherapy?

Digestive diseases and sciences, 2015-08, Vol.60 (8), p.2541-2543

2015

Volltextzugriff (PDF)

Psychological impact of Covid-19 pandemic on oncological patients: A survey in Northern Italy

PloS one, 2021-03, Vol.16 (3), p.e0248714

2021

Volltextzugriff (PDF)

Cost-effectiveness of pembrolizumab in first-line for microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancerF

Journal of oncology pharmacy practice, 2023-06, Vol.29 (4), p.958-961

2023

Volltextzugriff (PDF)

Dose-escalation strategy in refractory metastatic colorectal cancer: A change in terms of cost-effectiveness

Journal of oncology pharmacy practice, 2021-06, Vol.27 (4), p.974-977

2021

Volltextzugriff (PDF)

Economic sustainability of nivolumab at flat dose for second-line treatment of metastatic non-small cell lung cancer in real life

Journal of oncology pharmacy practice, 2019-12, Vol.25 (8), p.2059-2060

2019

Volltextzugriff (PDF)

Anatomy and Classification of Pelvic Trauma

Journal of Endovascular Resuscitation and Trauma Management, 2024-04

2024

Volltextzugriff (PDF)

Glioblastoma: Prognostic Factors and Predictive Response to Radio and Chemotherapy

Current medicinal chemistry, 2020, Vol.27 (17), p.2814-2825

2020

Volltextzugriff (PDF)

Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness

Clinical colorectal cancer, 2022-06, Vol.21 (2), p.e145-e147

Giuliani, Jacopo

2022

Volltextzugriff (PDF)

The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab

Anticancer research, 2019-07, Vol.39 (7), p.3971-3973

2019

Volltextzugriff (PDF)

Brigatinib is a cost-effective treatment in first-line anaplastic lymphoma kinase mutation-positive (ALK + ) advanced non-small cell lung cancer (NSCLC) with brain metastases

Journal of oncology pharmacy practice, 2022-04, Vol.28 (3), p.691-694

Giuliani, Jacopo

2022

Volltextzugriff (PDF)

Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors

Anticancer research, 2019-07, Vol.39 (7), p.3961-3965

2019

Volltextzugriff (PDF)

Which grade is of clinical benefit in the randomised controlled trials? The example of 54th American Society of Clinical Oncology annual meeting, 2018

European journal of cancer (1990), 2018-11, Vol.104, p.233-235

2018

Volltextzugriff (PDF)

Elderly patients with advanced pancreatic cancer: the generalizability of the results of clinical trials to daily clinical practice

Recenti progressi in medicina, 2017-03, Vol.108 (3), p.152

2017

Volltextzugriff (PDF)

1 – 25 von 221

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(205)
Mit Volltextzugriff
(190)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(165)
Life Sciences & Biomedicine
(155)
Humans
(126)
Oncology
(78)
Female
(55)
Male
(49)
Aged
(41)
Middle Aged
(38)
Medicine
(28)
Medicine & Public Health
(27)
Pharmacology & Pharmacy
(27)
Retrospective Studies
(27)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(24)
Adult
(23)
Aged, 80 And Over
(22)
Cost Of Drugs
(22)
Cell Biology
(21)
Inflammation
(21)
Clinical Trials
(19)
Metastases
(19)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer

Cost-effectiveness of denosumab in preventing skeletal-related events in bone metastases

Cost-effectiveness of immune checkpoint inhibitors and radiotherapy in advanced non-small cell lung cancer

Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data

Implications of drugs with rebate in Europe

The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma

Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer

Cost-effectiveness of maintenance therapy after first-line treatment in metastatic colorectal cancer

Netupitant plus palonosetron is a cost-effective treatment for the prophylaxis of chemotherapy-induced nausea and vomiting in highly and moderately emetogenic cancer treatment

Cost-effectiveness of consolidation durvalumab after chemo-radiotherapy in stage III non-small-cell lung cancer: A cost-effective change

Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer

Acute Liver Failure Caused by Metastatic Breast Cancer: Can We Expect Some Results from Chemotherapy?

Psychological impact of Covid-19 pandemic on oncological patients: A survey in Northern Italy

Cost-effectiveness of pembrolizumab in first-line for microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancerF

Dose-escalation strategy in refractory metastatic colorectal cancer: A change in terms of cost-effectiveness

Economic sustainability of nivolumab at flat dose for second-line treatment of metastatic non-small cell lung cancer in real life

Anatomy and Classification of Pelvic Trauma

Glioblastoma: Prognostic Factors and Predictive Response to Radio and Chemotherapy

Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness

The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab

Brigatinib is a cost-effective treatment in first-line anaplastic lymphoma kinase mutation-positive (ALK + ) advanced non-small cell lung cancer (NSCLC) with brain metastases

Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors

Which grade is of clinical benefit in the randomised controlled trials? The example of 54th American Society of Clinical Oncology annual meeting, 2018

Elderly patients with advanced pancreatic cancer: the generalizability of the results of clinical trials to daily clinical practice

Suchergebnisse filtern